SCHEMBL3619658

SCHEMBL3619658

C=Cc1cccc2c1ccn2S(=O)(=O)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 18/20 0.62
HDAC3 O15379 1/20 0.62
HDAC4 P56524 1/20 0.62
HDAC1 Q13547 1/20 0.62
HDAC7 Q8WUI4 1/20 0.62
HDAC2 Q92769 1/20 0.62
HDAC10 Q969S8 1/20 0.62
HDAC11 Q96DB2 1/20 0.62
HDAC8 Q9BY41 1/20 0.62
HDAC6 Q9UBN7 1/20 0.62
HDAC9 Q9UKV0 1/20 0.62
HDAC5 Q9UQL6 1/20 0.62
HTR1A P08908 3/20 0.56
HTR1D P28221 2/20 0.56
HTR1B P28222 2/20 0.56
HTR1F P30939 2/20 0.56
HTR7 P34969 2/20 0.56
DRD3 P35462 2/20 0.56
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021608 0.88 HDAC3 (0.51) HTR6HDAC3HDAC4HDAC1HDAC7
SCHEMBL3613863 0.87 HTR6 (0.53) HTR6HDAC3HDAC4HDAC1HDAC7
SCHEMBL3622901 0.87 KDM4E (0.58) HTR6HDAC3HDAC4HDAC1HDAC7
SCHEMBL28781696 0.87 HDAC3 (0.55) HTR6HDAC3HDAC4HDAC1HDAC7
SCHEMBL743239 0.87 HTR6 (0.64) HTR6HDAC3HDAC4HDAC1HDAC7
SCHEMBL4029769 0.85 HTR6 (0.62) HTR6HDAC3HDAC4HDAC1HDAC7
SCHEMBL3623408 0.84 HTR6 (0.48) HTR6HDAC3HDAC4HDAC1HDAC7
SCHEMBL14070488 0.83 HDAC3 (0.66) HTR6HDAC3HDAC4HDAC1HDAC7
SCHEMBL3613851 0.82 HTR6 (0.48) HTR6HDAC3HDAC4HDAC1HDAC7
SCHEMBL4023676 0.81 KDM4E (0.51) HTR6HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046741-B1 INDOLES AS 5-HT6 MODULATORS PROXIMAGEN LTD (GB) 2012-10-31 EP disclosed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US disclosed
CN-101484420-A Indoles as 5-HT 6 modulators BIOVITRUM AB PUBL (SE) 2009-07-15 CN disclosed
EP-2046741-A1 INDOLES AS 5-HT6 MODULATORS BIOVITRUM AB (publ) (SE) 2009-04-15 EP disclosed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US disclosed
WO-2008003703-A1 INDOLES AS 5-HT6 MODULATORS BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032968-A1 New compounds HTR6, HTR1B, HTR1A HTR6 1/4885HDAC3 1122/4885HDAC4 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.